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TO THE EDITOR
Melanoma occurs in approximately
10% of cases in families with multiple
affected members (De Snoo et al.,
2003). In 20–57% of patients tumor
susceptibility can be attributed to germ-
line inactivating mutations in an allele
of the CDKN2A gene (Goldstein et al.,
2007). A small minority of patients is
predisposed to the development of
melanoma through activating mutations
in the CDK4 gene (Goldstein et al.,
2006). However, in most cases of
familial melanoma the genetic defect
predisposing to melanoma develop-
ment is unknown, which impedes
genetic counseling. The CDKN2A gene
encodes the p16 and p14ARF tumor
suppressor proteins by means of differ-
ent promoters and reading frames.
Inactivation of p16 function through
deletion, point mutation or promoter
hypermethylation is a common and
critical event in the pathogenesis of
melanoma (Sharpless and Chin, 2003;
Singh et al., 2008). In addition, p14ARF
may be genetically or epigenetically
inactivated in sporadic melanoma and
germline mutations in CDKN2A solely
affecting p14ARF function have been
identified in familial melanoma (Har-
land et al., 2005; Furuta et al., 2006).
Patients with familial melanoma not
related to germline mutation in
CDKN2A or CDK4 cannot be distin-
guished on the basis of clinical features.
Germline mutations in different genes
are assumed as a cause of melanoma
predisposition in these patients (Bishop
et al., 2007).
Recently, an alternative mechanism
of tumor predisposition, epimutation or
germline promoter hypermethylation,
has been found. In a subset of patients
with hereditary nonpolyposis colorectal
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cancer who did not harbor mutations in
the MLH1 or MSH2 susceptibility
genes, promoter hypermethylation of
one allele of the MLH1 gene was
demonstrated in nearly all somatic
cells, originating in the germline (Suter
et al., 2004; Martin et al., 2005).
Promoter hypermethylation is asso-
ciated with transcriptional silencing
and leads to functional inactivation of
the affected allele. Although some
uncertainty has remained concerning
the exact mechanisms and patterns of
inheritance of these epigenetic altera-
tions, transmission of germline epimu-
tation of MLH1 to offspring has been
demonstrated (Hitchins et al., 2007).
The purpose of this study has been to
evaluate if melanoma predisposition
might be caused by germline epimuta-
tion of the CDKN2A gene, in those
cases not associated with germline
mutations in CDKN2A or CDK4.
We selected 22 unrelated Dutch
patients with familial melanoma, in
whom melanoma had developed and
who had at least one first-degree or two
otherwise related family members diag-
nosed with melanoma (Table 1). Muta-
tions in CDKN2A had been excluded
by sequence analysis of its exons and
introns. Also exon 2 of CDK4, harbor-
ing activating hotspot mutations, was
analyzed in these patients. The promo-
ters of p16 and p14ARF were analyzed
for hypermethylation using two com-
plementary methods: methylation-spe-
cific melting curve analysis (MS-MCA)
and direct bisulfite sequence analysis
(BSA; Paul and Clark, 1996; Worm
et al., 2001). Sensitivity of MS-MCA
and BSA was validated by detection of
p16 and p14ARF methylation in mix-
tures of methylated DNA (Chemicon,
Hampshire, UK) and unmethylated se-
men DNA as well as in DNA from the
colon cancer cell lines Colo205 and
SW48, previously demonstrated to ex-
hibit promoter hypermethylation of p16
and p14ARF, respectively (Zheng et al.,
2000). DNA from patients with familial
melanoma was isolated from peripheral
blood mononuclear cells (PBMCs).
DNA (1mg) was bisulfite-converted
using the EZ DNA methylation kit
(Zymo Research, Orange, CA). Primer
sequences were designed to amplify
CpG islands located in promoter re-
gions of p16 and p14ARF and are
available upon request (Figure 1a).
Amplicons, both containing 10 CpG
dinucleotides, were analyzed by MS-
MCA and BSA. For MS-MCA, following
PCR amplification DNA melting curves
were acquired on a MyiQ real-time
PCR detection system by measuring the
fluorescence of SYBR Green during a
temperature transition from 65 to 95 1C.
BSA was performed as previously de-
scribed (Van Doorn et al., 2005). The
studies were approved by the Leiden
University Medical Center institutional
review board and were conducted ac-
cording to the Declaration of Helsinki
Principles. Patient consent was obtained.
MS-MCA of the unmethylated p16
promoter sequence results in a peak
with a melting temperature (Tm) of
79.6 1C, whereas the methylated se-
quence results in a Tm of 82.8 1C. For
the p14ARF promoter, the Tm is 81.2 1C
for the unmethylated sequence and
84.6 1C in case of methylation. De-
picted in Figure 1b are melting curve
profiles for the p16 and p14ARF promo-
ters of a mixture containing 50%
methylated DNA and 50% unmethy-
lated DNA showing two Tm peaks in the
upper graphs and for DNA from the
cancer cell lines in the middle graphs.
Melting curve profiles of DNA samples
isolated from PBMCs of 22 patients
with familial melanoma are presented
in the lower graphs. All patient samples
showed melting curve profiles with a
Tm of 79.6 1C for p16 and 81.2 1C for
p14ARF, indicating that the CpG islands
in the promoters of p16 and p14ARF
contained no or scarcely any methy-
lated CpG dinucleotides. To confirm
these findings, PCR products of the 22
bisulfite-converted DNA samples were
subjected to sequence analysis. BSA
showed that indeed CpG dinucleotides
in the p16 or p14ARF promoter were not
methylated in any of the patient sam-
ples (Figure 1c).
Taken together our results indicate
that at least in the Dutch population
familial melanoma is not caused by
Table 1. Characteristics of included patients with familial melanoma
Patient number Gender Age at diagnosis Affected family members
1 Female 49 Mother, two daughters
2 Female 39 Two sisters, one aunt, one female cousin
3 Male 25 Grandfather, two uncles
4 Female 27 Brother, one female cousin
5 Female 32 Mother, third-degree relative
6 Female 40 Son, brother
7 Female 54 Two sisters, one female cousin
8 Male 28 Father, mother, sister
9 Male 54 Daughter, one female cousin
10 Male 48 Two sisters, brother
11 Male 63 Sister, female cousin
12 Male 27 Sister, aunt, uncle
13 Female 58 Son
14 Female 40 Brother
15 Male 40 Sister
16 Male 30 Father
17 Male 60 Daughter
18 Male 63 Daughter
19 Male 42 Two female cousins, male cousin
20 Female 72 Daughter
21 Male 52 Sister, female cousin
22 Female 45 Twin brother
782 Journal of Investigative Dermatology (2009), Volume 129
R van Doorn et al.
Absence of Germline Epimutation of the CDKN2A Gene
germline epimutation of CDKN2A, in
patients who lack mutations in this
tumor suppressor gene. Although we
have found no evidence of direct germ-
line hypermethylation of CDKN2A
gene promoters as a mechanism of
tumor predisposition, other potentially
heritable epigenetic events affecting the
CDKN2A gene cannot be entirely ex-
cluded. The hypothesis has been ad-
vanced that alleles of certain genes,
such as MSH2 in a subset of patients
with hereditary nonpolyposis colorectal
cancer, may be prone to somatic
hypermethylation because of their
genetic or local chromatin structure,
which would be associated with epige-
netic silencing confined to specific
tissues (Chan et al., 2006; Suter and
Martin, 2007). In this study, we exclude
heritable epigenetic inactivation of
CDKN2A as a mechanism causing
susceptibility to the development of
melanoma. The observed absence of
CDKN2A epimutation implies that in
patients with familial melanoma not
related to mutations in this gene or in
CDK4, heritable defects in other genes
are implicated. The identification of
additional melanoma susceptibility
genes is currently actively pursued
through genome-wide association stu-
dies on large groups of patients.
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Figure 1. Methylation status of the p16 and p14ARF promoters of the CDKN2A gene. (a) Schematic
representation of the promoter regions of p16 and p14ARF indicating the sequence amplified for MS-MCA
and BSA, location of the CpG island and transcription start site (TSS). (b) MS-MCA melting curve profiles
for mixtures of 50% completely methylated and 50% unmethylated bisulfite-converted DNA showing
two peaks for the methylated (m) and unmethylated (u) DNA fraction, used as control (upper graphs).
Melting curve profiles for the Colo205 and SW48 colon carcinoma cell showing biallelic
hypermethylation of the p16 and monoallelic methylation of the p14ARF promoter, respectively (middle
graphs). MS-MCA results of the 22 patient DNA samples plotted jointly in one graph, showing a single
peak at the Tm for unmethylated DNA (lower graphs). (c) Methylation density maps generated using BSA
results of the p16 and p14ARF CpG island amplicons. BSA of mixtures of completely methylated and
unmethylated DNA: methylation could be detected when mixtures contained as little as 25% methylated
DNA. In the patient samples none of the 10 interrogated CpG dinucleotides showed methylation (patient
samples). Unmethylated cytosine bases are indicated as (J), methylated cytosines as (K).
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TO THE EDITOR
Tanning results from a coordinated set
of signals that induce skin hyperpig-
mentation in response to exposure to
UV radiation (Park et al., 2008). This is
classically thought to occur through the
actions of proopiomelanocortin-de-
rived peptides and a-melanocyte stimu-
lating hormone (Abe et al., 1969a, b;
Wakamatsu et al., 1997; Thody and
Graham, 1998; Slominski et al., 2000,
2004; Tsatmali et al., 2000; Rousseau
et al., 2007) on the melanocyte mela-
nocortin-1 receptor by increasing in-
tracellular cAMP (Im et al., 1998).
However, as studies in proopiomelano-
cortin-deficient mice have shown that
these mice retain the capacity to
produce eumelanin even in the
absence of a-melanocyte stimulating
hormone or proopiomelanocortin-re-
lated peptides (Smart and Low, 2003;
Slominski et al., 2005), and animals
with a nonfunctional melanocortin-1
receptor are still able to produce
melanin in response to forskolin (Fried-
mann et al., 1990; D’Orazio et al.,
2006), it is likely that alternate cAMP-
dependent pathways can induce
melanogenesis.
One alternate cAMP-dependent path-
way involves the adrenergic receptor.
The adrenergic receptors are pharmaco-
logically divided into two subgroups, a
and b, and both receptor subfamilies
have been implicated in the control of
pigmentation in frog skin (McGuire,
1970; Taylor and Teague, 1976) and
human uveal melanocytes (Hu, 2000;
Hu et al., 2000). Human epidermal
melanocytes express the a1-adrenergic
receptor and b2-adrenergic receptor
(B2AR; Schallreuter et al., 1996; Scar-
paro et al., 2000), and activation of the
B2AR was shown to increase melanin
synthesis (Gillbro et al., 2004) whereas
activation of the a1-adrenergic receptor
had no effect (Schallreuter et al., 1996).
Human melanocytes also increase their
expression of the B2AR in response to
UV irradiation (Yang et al., 2006),
further suggesting a role for the B2AR
in UV-induced hyperpigmentation.
Catecholamines are endogenous li-
gands for the adrenergic receptor and
epinephrine has the greatest affinity for
the B2AR. Indeed, epinephrine has
been shown to increase melanin synth-
esis in human uveal melanocytes (Hu
et al., 2000) and increase intracellular
cAMP in human epidermal melano-
cytes (Gillbro et al., 2004). Epidermal
melanocytes can synthesize the cate-
cholamine norepinephrine but are un-
able to produce epinephrine as they do
not express the enzyme phenylethano-
lamine-N-methyltransferase, which is
necessary for synthesis of epinephrine
(Gillbro et al., 2004). Norepinephrine,
though synthesized by melanocytes,
does not seem to alter melanogenesis
(Schallreuter et al., 1996). However,
keratinocytes possess the capacity to
synthesize epinephrine (Schallreuter
et al., 1992; Pullar et al., 2006). Thus,
we hypothesized the existence of a
paracrine interaction whereby keratino-
cytes secrete epinephrine in response to
UV irradiation, which could then sti-
mulate neighboring b-adrenergic recep-
tors (BARs) on melanocytes to increase
melanin synthesis.
Primary human keratinocytes and
melanocytes were isolated from human
neonatal foreskin and cultured in kerati-
nocyte serum-free media (Cascade Biolo-
gics, Portland, OR) and phorbol-free
Abbreviations: B2AR, b2-adrenergic receptor; BAR, b-adrenergic receptor; PBS, phosphate buffer
solution
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